(10aS,12aS)-10a,12a-dimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (10aS,12aS)-10a,12a-dimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol
• 英文别名: (2S,18S)-2,18-dimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol
• 化学式: C₂₀H₃₀N₂O
• 分子量: 314.5
• InChiKey: GZCJWTCFQKPYQN-YEOBYHGESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Methods and products for treatment of diseases
  申请人：DMI Biosciences, Inc.

  公开号：EP2468282A2

  公开（公告）日：2012-06-27

  The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.

  本发明涉及用有效量的具有说明书中所述配方的类固醇或其药理学上可接受的盐或酯来治疗疾病和病症。根据本发明，可治疗的疾病或病症包括眼部血管生成性疾病和病症、脑部血管生成性疾病和病症、眼部炎症性疾病和病症、脑部炎症性疾病和病症以及神经退行性疾病。